Related Experiment Videos
Phase I study of amonafide dosing based on acetylator phenotype
M J Ratain1, R Mick, F Berezin
1Department of Medicine, University of Chicago Pritzker School of Medicine, Illinois 60637.
Cancer Research
|May 15, 1993
Summary
Determining the correct amonafide dose is crucial for cancer patients. This study recommends specific phase II doses for fast and slow acetylators to minimize toxicity and maximize efficacy.
Failed At:
2026-06-19T13:41:01.780294+00:00